Alteration of immune profiles is associated with pulmonary function and symptoms in patients with chronic obstructive pulmonary disease

Li,Sixiang; Zhao,Shuang; Wu,Zhenru; Wang,Fangfang; Li,Weimin

doi:10.3892/mmr.2021.12382

Alteration of immune profiles is associated with pulmonary function and symptoms in patients with chronic obstructive pulmonary disease

Authors:
- Sixiang Li
- Shuang Zhao
- Zhenru Wu
- Fangfang Wang
- Weimin Li
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Pathology Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: August 24, 2021 https://doi.org/10.3892/mmr.2021.12382
Article Number: 742
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation serves a key role in chronic obstructive pulmonary disease (COPD). However, changes in the immune profiles of patients with COPD remain unclear. The present prospective observational study aimed to determine the expression profiles of immune cells and inflammatory factors of patients with COPD and healthy controls, and to analyze the relationship between immune profiles and smoking history. A total of 140 subjects were enrolled in the present study between September 2018 and April 2019 at West China Hospital of Sichuan University (Chengdu, China). These included 87 patients with stable COPD and 24 patients with acute exacerbated COPD, as well as 29 healthy controls. Baseline characteristics were recorded during the screening period, and levels of immune cells were examined using flow cytometry. In addition, levels of inflammatory factors were measured using ELISAs. The results revealed increased expression of the CD64⁺/CD14⁺ mononuclear phagocyte system (MPS) and CD16⁺CD66⁺ neutrophils, and decreased expression of CD3⁺CD4⁺ T cells and CD3⁺ CD8⁺ T cells (all P<0.05) in the peripheral blood of patients with COPD and smokers relative to non‑smoking controls. In addition, significant differences were observed in protein levels of IL‑6, IL‑1β, TNF‑α, TGF‑α, IFN‑γ, IL‑8, IL‑17A and CRP among the three groups (all P<0.05). Furthermore, the IL‑17A, TNF and NF‑κB signaling pathways were found to serve a key role in the inflammatory network of COPD. Pearson's correlation analysis revealed a positive correlation between CD3⁺T lymphocyte counts and pulmonary function, and a negative correlation with smoking and exacerbations. Furthermore, neutrophils and MPS were negatively associated with pulmonary function, and IL‑8 was positively associated with cough. There was also a negative association between CRP and IL‑17A with pulmonary function but a positive correlation with symptoms and exacerbation. Club cell secretory protein was also negatively associated with emphysema parameters. In conclusion, the present findings revealed significant differences in profiles of immune factors among patients with COPD, smokers and non‑smoking controls and their association with clinical characteristics. The clinical trial registration number of the present study is: ChiCTR1800015700 (registered with http://www.chictr.org.cn/index.aspx, 2018/04/16).

View Figures

View References

1	GBD 2017 Causes of Death Collaborators, . Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392:1736–1788. 2018. View Article : Google Scholar : PubMed/NCBI
2	Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: The GOLD science committee report 2019. Eur Respir J. 53:19001642019. View Article : Google Scholar : PubMed/NCBI
3	Decramer M, Janssens W and Miravitlles M: Chronic obstructive pulmonary disease. Lancet. 379:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tuder RM and Petrache I: Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 122:2749–2755. 2012. View Article : Google Scholar : PubMed/NCBI
5	Brightling C and Greening N: Airway inflammation in COPD-progress to precision medicine. Eur Respir J. 54:19006512019. View Article : Google Scholar : PubMed/NCBI
6	Gorska K, Paplinska-Goryca M, Nejman-Gryz P, Goryca K and Krenke R: Eosinophilic and neutrophilic airway inflammation in the phenotyping of mild-to-moderate asthma and chronic obstructive pulmonary disease. COPD. 14:181–189. 2017. View Article : Google Scholar : PubMed/NCBI
7	Magnussen H: Therapy control of COPD by eosinophilic granulocytes? Dtsch Med Wochenschr. 144:917–921. 2019.(In German). PubMed/NCBI
8	Pavord ID: Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 141:1983–1991. 2018. View Article : Google Scholar : PubMed/NCBI
9	Yousuf A and Brightling CE: Biologic drugs: A new target therapy in COPD? COPD. 15:99–107. 2018. View Article : Google Scholar : PubMed/NCBI
10	Cruz T, Lopez-Giraldo A, Noell G, Casas-Recasens S, Garcia T, Molins L, Juan M, Fernandez MA, Agustí A and Faner R: Multi-level immune response network in mild-moderate chronic obstructive pulmonary disease (COPD). Respir Res. 20:1522019. View Article : Google Scholar : PubMed/NCBI
11	Pan Z, Yu H and Liao JL: Probing cellular and molecular mechanisms of cigarette smoke-induced immune response in the progression of chronic obstructive pulmonary disease using multiscale network modeling. PLoS One. 11:e01631922016. View Article : Google Scholar : PubMed/NCBI
12	Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, Wootton M, Hood K, Phillips R, Melbye H, et al: C-Reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 381:111–120. 2019. View Article : Google Scholar : PubMed/NCBI
13	Bradford E, Jacobson S, Varasteh J, Comellas AP, Woodruff P, O'Neal W, DeMeo DL, Li X, Kim V, Cho M, et al: The value of blood cytokines and chemokines in assessing COPD. Respir Res. 18:1802017. View Article : Google Scholar : PubMed/NCBI
14	Regan EA, Hersh CP, Castaldi PJ, DeMeo DL, Silverman EK, Crapo JD and Bowler RP: Omics and the search for blood biomarkers in Chronic obstructive pulmonary disease: Insights from COPDGene. Am J Respir Cell Mol Biol. 61:143–149. 2019. View Article : Google Scholar : PubMed/NCBI
15	Zou Y, Chen X, Liu J, Zhou DB, Kuang X, Xiao J, Yu Q, Lu X, Li W, Xie B and Chen Q: Serum IL-1β and IL-17A levels in patients with COPD: Associations with clinical parameters. Int J Chron Obstruct Pulmon Dis. 12:1247–1254. 2017. View Article : Google Scholar : PubMed/NCBI
16	Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, Schuetz P, Watz H, Waschki B, Müllerova H, et al: Biomarkers and clinical outcomes in COPD: A systematic review and meta-analysis. Thorax. 74:439–446. 2019. View Article : Google Scholar : PubMed/NCBI
17	Bai Y, Zhou Q, Fang Q, Song L and Chen K: Inflammatory cytokines and T-Lymphocyte subsets in serum and sputum in patients with bronchial asthma and chronic obstructive pulmonary disease. Med Sci Monit. 25:2206–2210. 2019. View Article : Google Scholar : PubMed/NCBI
18	Papaioannou AI, Konstantelou E, Papaporfyriou A, Bartziokas K, Spathis A, Bakakos P, Loukides S, Koulouris N, Papiris S and Kostikas K: Serum surfactant protein levels in patients admitted to the hospital with acute COPD exacerbation. Lung. 196:201–205. 2018. View Article : Google Scholar : PubMed/NCBI
19	Zhai J, Insel M, Addison KJ, Stern DA, Pederson W, Dy A, Rojas-Quintero J, Owen CA, Sherrill DL, Morgan W, et al: Club cell secretory protein deficiency leads to altered lung function. Am J Respir Crit Care Med. 199:302–312. 2019. View Article : Google Scholar : PubMed/NCBI
20	Rangasamy L, Geronimo BD, Ortin I, Coderch C, Zapico JM, Ramos A and de Pascual-Teresa B: Molecular imaging probes based on matrix metalloproteinase inhibitors (MMPIs). Molecules. 24:29822019. View Article : Google Scholar : PubMed/NCBI
21	Stockley RA, Halpin DMG, Celli BR and Singh D: Chronic obstructive pulmonary disease Biomarkers and their interpretation. Am J Respir Crit Care Med. 199:1195–1204. 2018. View Article : Google Scholar : PubMed/NCBI
22	Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, et al: Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 200:e70–e88. 2019. View Article : Google Scholar : PubMed/NCBI
23	Munari AB, Gulart AA, Dos Santos K, Venâncio RS, Karloh M and Mayer AF: Modified medical research council dyspnea scale in GOLD classification better reflects physical activities of daily living. Respir Care. 63:77–85. 2018. View Article : Google Scholar : PubMed/NCBI
24	Skierka AS and Michels KB: Ethical principles and placebo-controlled trials-interpretation and implementation of the Declaration of Helsinki's placebo paragraph in medical research. BMC Med Ethics. 19:242018. View Article : Google Scholar : PubMed/NCBI
25	Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019. View Article : Google Scholar : PubMed/NCBI
26	Caramori G, Casolari P, Barczyk A, Durham AL, Di Stefano A and Adcock I: COPD immunopathology. Semin Immunopathol. 38:497–515. 2016. View Article : Google Scholar : PubMed/NCBI
27	Cruz T, Lopez-Giraldo A, Noell G, Molins L, Juan M, Fernandez MA, Canet MRF and Agusti A: Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD. Eur Respiratory J Conf. 50:2017.
28	Hume DA, Irvine KM and Pridans C: The mononuclear phagocyte system: The relationship between monocytes and macrophages. Trends Immunol. 40:98–112. 2019. View Article : Google Scholar : PubMed/NCBI
29	Yang J, Zhang L, Yu C, Yang XF and Wang H: Monocyte and macrophage differentiation: Circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res. 2:12014. View Article : Google Scholar : PubMed/NCBI
30	Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, Chen TH, Quibrera PM, Anderson W, Barr RG, et al: Common genetic polymorphisms influence blood biomarker measurements in COPD. PLoS Genet. 12:e10060112016. View Article : Google Scholar : PubMed/NCBI
31	Mannino DM: Biomarkers for chronic obstructive pulmonary disease diagnosis and progression: Insights, disappointments and promise. Curr Opin Pulm Med. 25:144–149. 2019. View Article : Google Scholar : PubMed/NCBI
32	Garudadri S and Woodruff PG: Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc. 15 (Suppl 4):S234–S238. 2018. View Article : Google Scholar : PubMed/NCBI
33	Lee S, Ro H, In HJ, Choi JH, Kim MO, Lee J, Hong ST and Lee SU: Fisetin inhibits TNF-α/NF-κB-induced IL-8 expression by targeting PKCδ in human airway epithelial cells. Cytokine. 108:247–254. 2018. View Article : Google Scholar : PubMed/NCBI
34	Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, Barr RG, Bleecker ER, et al: An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup. J Clin Invest. 129:169–181. 2019. View Article : Google Scholar : PubMed/NCBI
35	Roos AB, Sanden C, Mori M, Bjermer L, Stampfli MR and Erjefalt JS: IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med. 191:1232–1241. 2015. View Article : Google Scholar : PubMed/NCBI
36	Zheng X, Zhang L, Chen J, Gu Y, Xu J and Ouyang Y: Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease. Biomed Pharmacother. 108:1141–1151. 2018. View Article : Google Scholar : PubMed/NCBI
37	Ito JT, Cervilha DAB, Lourenco JD, Goncalves NG, Volpini RA, Caldini EG, Landman G, Lin CJ, Velosa APP, Teodoro WPR, et al: Th17/Treg imbalance in COPD progression: A temporal analysis using a CS-induced model. PLoS One. 14:e02093512019. View Article : Google Scholar : PubMed/NCBI
38	Li XN, Pan X and Qiu D: Imbalances of Th17 and Treg cells and their respective cytokines in COPD patients by disease stage. Int J Clin Exp Med. 7:5324–5329. 2014.PubMed/NCBI